{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06181136",
            "orgStudyIdInfo": {
                "id": "DNLI-I-0001"
            },
            "organization": {
                "fullName": "Denali Therapeutics Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)",
            "officialTitle": "A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-of-in-pediatric-participants-with-mucopolysaccharidosis-type-iiia-sanfilippo-syndrome-type-a"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-04",
            "studyFirstSubmitQcDate": "2023-12-22",
            "studyFirstPostDateStruct": {
                "date": "2023-12-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Denali Therapeutics Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a multicenter, open-label, Phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and exploratory clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). The core study period is 25 weeks (approximately 6 months) and is followed by a 72-week (approximately 18 month) open-label extension (OLE)."
        },
        "conditionsModule": {
            "conditions": [
                "Mucopolysaccharidosis Type IIIA"
            ],
            "keywords": [
                "Sanfilippo Syndrome",
                "MPS IIIA"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 8,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort A1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with MPS IIIA",
                    "interventionNames": [
                        "Drug: DNL126"
                    ]
                },
                {
                    "label": "Cohort A2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with MPS IIIA",
                    "interventionNames": [
                        "Drug: DNL126"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "DNL126",
                    "description": "intravenous repeating dose",
                    "armGroupLabels": [
                        "Cohort A1",
                        "Cohort A2"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs)",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Number of participants with clinically significant treatment emergent laboratory test abnormalities.",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Number of participants with treatment emergent vital sign abnormalities.",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Number of participants with clinically significant treatment emergent abnormalities in 12-lead ECG results.",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Number of participants with clinically significant treatment emergent abnormalities in physical examination.",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Number of participants with clinically significant treatment emergent abnormalities in neurological examination.",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Incidence and severity of infusion-related reactions (IRRs)",
                    "timeFrame": "Up to 97 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage change from baseline in cerebrospinal fluid (CSF) concentration of heparan sulfate (HS)",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Participants with CSF HS concentration within the normal range",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Percentage change from baseline in urine concentration of HS (normalized to creatinine)",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Participants with urine HS concentration (normalized to creatinine) within the normal range",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Participants with liver volume within the normal range",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Change from baseline in liver volume",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Participants with spleen volume within the normal range",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Change from baseline in spleen volume",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Maximum concentration (Cmax)",
                    "description": "DNL126 serum PK parameters",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "time to maximum observed concentration (Tmax)",
                    "description": "DNL126 serum PK parameters",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUClast)",
                    "description": "DNL126 serum PK parameters",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "area under the concentration-time curve from time zero to infinity (AUC\u221e; single dose only)",
                    "description": "DNL126 serum PK parameters",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "DNL126 serum PK parameters",
                    "description": "area under the concentration-time curve over a dosing interval (AUC\u03c4; multiple doses only)",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "apparent terminal elimination half-life (t\u00bd)",
                    "description": "DNL126 serum PK parameters",
                    "timeFrame": "Up to 97 weeks"
                },
                {
                    "measure": "Incidence of anti-drug antibodies (ADAs) relative to baseline",
                    "timeFrame": "Up to 97 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Confirmed diagnosis of MPS IIIA\n\nKey Exclusion Criteria:\n\n* Have unstable or poorly controlled medical condition(s) or significant medical or psychological comorbidity or comorbidities that, in the opinion of the investigator, would interfere with safe participation in the trial or interpretation of study assessments\n* Have lost the ability to walk independently, in the opinion of the investigator\n* Are unable to take the majority of nutrition via mouth, in the opinion of the investigator\n* Have used any CNS-targeted MPS IIIA enzyme replacement therapy (ERT) (eg, intrathecal SGSH or TfR-mediated SGSH delivery to CNS) within 3 months before Day 1\n* Have a prior history of hematopoietic stem cell transplantation\n* Have a prior history of gene therapy\n* Have used genistein within 30 days of screening or intended use of genistein during the study\n* Have a documented likely pathogenic mutation sufficient to cause disease (eg, taking into account zygosity) of other genes that are known to be associated with developmental delay, seizures, or other significant CNS disorders\n* Have clinically significant thrombocytopenia, other clinically significant coagulation abnormality, significant active bleeding, or require treatment with an anticoagulant or more than two antiplatelet agents\n* Contraindication for lumbar punctures\n* Contraindication for MRI scan\n* Have a clinically significant history of stroke, status epilepticus, head trauma with loss of consciousness, or any clinically significant CNS disease that is not MPS IIIA-related within 3 months of screening\n* Have had a ventriculoperitoneal (VP) shunt placed or a clinically significant VP shunt malfunction within 30 days of screening\n* Have any clinically significant CNS trauma or disorder, including severe untreated intracranial hypertension or brain surgery, that, in the opinion of the investigator, may interfere with assessment of study endpoints or make participation in the study unsafe",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "2 Years",
            "maximumAge": "18 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials at Denali Therapeutics",
                    "role": "CONTACT",
                    "phone": "Email",
                    "email": "clinical-trials@dnli.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Steven Chessler, MD, PhD",
                    "affiliation": "Denali Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCSF Benioff Children's Hospital Oakland",
                    "status": "RECRUITING",
                    "city": "Oakland",
                    "state": "California",
                    "zip": "94609",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alyssa Kohler",
                            "role": "CONTACT",
                            "phone": "510-428-3885",
                            "phoneExt": "7442",
                            "email": "alyssa.kohler@ucsf.edu"
                        },
                        {
                            "name": "Paul Harmatz, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.80437,
                        "lon": -122.2708
                    }
                },
                {
                    "facility": "University of Iowa Stead Family Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Iowa City",
                    "state": "Iowa",
                    "zip": "52242",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lindsey Reinhardt",
                            "role": "CONTACT",
                            "phone": "319-467-8197",
                            "email": "lindsey-reinhardt@uiowa.edu"
                        },
                        {
                            "name": "John Bernat, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.66113,
                        "lon": -91.53017
                    }
                },
                {
                    "facility": "University of North Carolina at Chapel Hill",
                    "status": "RECRUITING",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "27514",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lindsay Torrice",
                            "role": "CONTACT",
                            "phone": "919-966-1135",
                            "email": "Lindsay_torrice@med.unc.edu"
                        },
                        {
                            "name": "Elizabeth Jalazo, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "Baylor College of Medicine and Texas Children's Hospita",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Maria Nunez",
                            "role": "CONTACT",
                            "phone": "832-826-2097",
                            "email": "maria.nunez@bcm.edu"
                        },
                        {
                            "name": "Jimmy Holder, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009083",
                    "term": "Mucopolysaccharidoses"
                },
                {
                    "id": "D000009084",
                    "term": "Mucopolysaccharidosis III"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002239",
                    "term": "Carbohydrate Metabolism, Inborn Errors"
                },
                {
                    "id": "D000008661",
                    "term": "Metabolism, Inborn Errors"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000016464",
                    "term": "Lysosomal Storage Diseases"
                },
                {
                    "id": "D000017520",
                    "term": "Mucinoses"
                },
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M12041",
                    "name": "Mucopolysaccharidoses",
                    "asFound": "Mucopolysaccharidosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12042",
                    "name": "Mucopolysaccharidosis III",
                    "asFound": "Mucopolysaccharidosis Type IIIA",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11641",
                    "name": "Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M5498",
                    "name": "Carbohydrate Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M18871",
                    "name": "Lysosomal Storage Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19781",
                    "name": "Mucinoses",
                    "relevance": "LOW"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3901",
                    "name": "Mucopolysaccharidosis",
                    "asFound": "Mucopolysaccharidosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3904",
                    "name": "Mucopolysaccharidosis Type III",
                    "asFound": "Sanfilippo Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3905",
                    "name": "Mucopolysaccharidosis Type IIIA",
                    "asFound": "Mucopolysaccharidosis Type IIIA",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}